Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters
2022 · Cell Research · 55 citations
https://doi.org/10.1038/s41422-022-00630-0
S
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
23
Papers
597
Citations
12
h-index
14
i10-index
Shulong Zu is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: Mosquito-borne diseases and control & SARS-CoV-2 and COVID-19 Research & Viral Infections and Vectors. The author has an h-index of 12, co-authored 20 publications.
Papers by this author
worksADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12
2021 · Cell & Bioscience · 33 citations
https://doi.org/10.1186/s13578-021-00628-y
TRIM22 suppresses Zika virus replication by targeting NS1 and NS3 for proteasomal degradation
2022 · Cell & Bioscience · 28 citations
https://doi.org/10.1186/s13578-022-00872-w
Type-IInterferon-Inducible SERTAD3 Inhibits Influenza A Virus Replication by Blocking the Assembly of Viral RNA Polymerase Complex
2020 · Cell Reports · 24 citations
https://doi.org/10.1016/j.celrep.2020.108342
Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry
2021 · Signal Transduction and Targeted Therapy · 22 citations
https://doi.org/10.1038/s41392-021-00853-4
Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants
2022 · Cell & Bioscience · 10 citations
https://doi.org/10.1186/s13578-022-00794-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat